TLR9 agonist oligonucleotide immunotherapy (SNA) (Exicure)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTLR9 agonist oligonucleotide immunotherapy (SNA) (Exicure)
Drug Alias NameTLR9 agonists (Exicure)spherical nucleic acid immunotherapy (Exicure)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesExicure Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesExicure Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A